Galapagos Sees Global Market For Point-Of-Care CAR-T But Is Still On M&A Trail
CEO Hires Ex J&J Colleague To Continue Company Reinvention
Executive Summary
Paul Stoffels is continuing his transformation of Galapagos into a company with CAR-T and small molecule platforms and is aiming to seal more M&A deals before the end of this year.
You may also be interested in...
Deal Watch: Novartis, Ionis Team Up Again In Cardiovascular Disease
Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.
Kite Charts Path For Sustainable Access To Yescarta In Singapore
Kite’s senior director and head of medical affairs, Intercontinental Region, Tony Li, talks to Scrip about the company's efforts to enable timely and broad access to Yescarta in Singapore, where wider cancer drug procurement prices have declined following policy changes. A patient is already on course to being prepped for Kite's CAR-T cell therapy.
Galapagos Loses Potential Ticket To America As Crohns Trial Flops
The company reported the Phase III DIVERSITY trial of Jyseleca did not meet its primary endpoint in Crohn’s disease, closing another path to the US market.